Loading…

Infliximab in the treatment of patients with Crohn's disease: preliminary report

Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess th...

Full description

Saved in:
Bibliographic Details
Published in:Revista medíca de Chile 2006-03, Vol.134 (3), p.320-325
Main Authors: Gellona V, José, Zarraonandia A, Antón, Zúñiga D, Alvaro, Palma C, Renato, Contreras P, Jaime, Silva Ch, Jaime, González D, Róbinson, Quintana V, Carlos
Format: Article
Language:Spanish
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 325
container_issue 3
container_start_page 320
container_title Revista medíca de Chile
container_volume 134
creator Gellona V, José
Zarraonandia A, Antón
Zúñiga D, Alvaro
Palma C, Renato
Contreras P, Jaime
Silva Ch, Jaime
González D, Róbinson
Quintana V, Carlos
description Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess the effectiveness of Infliximab in patients with Crohn's disease. Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67941142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67941142</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-8d5a2cf0af421a5a999009245a5b252dfe2c0b8ab78593f649dc1cff50dcb6ac3</originalsourceid><addsrcrecordid>eNo1kM1KxDAYRbNQnHH0FSQrXRWSNGkbd1L8GRjQha7L1_QLjfQnJik6b2_BcXXP4nDh3jOyZSyXma6qckMuY_xkTJQFry7IhhfFSkxuydt-soP7cSO01E009UhTQEgjTonOlnpIbsVIv13qaR3mfrqLtHMRIeI99QEHN7oJwpEG9HNIV-TcwhDx-pQ78vH0-F6_ZIfX5339cMg8z3XKqk6BMJaBlYKDAq01Y1pIBaoVSnQWhWFtBW1ZKZ3bQurOcGOtYp1pCzD5jtz-9fowfy0YUzO6aHAYYMJ5iU1Rasm5FKt4cxKXdsSu8WEdG47N_wf5LzecWGY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67941142</pqid></control><display><type>article</type><title>Infliximab in the treatment of patients with Crohn's disease: preliminary report</title><source>SciELO</source><creator>Gellona V, José ; Zarraonandia A, Antón ; Zúñiga D, Alvaro ; Palma C, Renato ; Contreras P, Jaime ; Silva Ch, Jaime ; González D, Róbinson ; Quintana V, Carlos</creator><creatorcontrib>Gellona V, José ; Zarraonandia A, Antón ; Zúñiga D, Alvaro ; Palma C, Renato ; Contreras P, Jaime ; Silva Ch, Jaime ; González D, Róbinson ; Quintana V, Carlos</creatorcontrib><description>Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess the effectiveness of Infliximab in patients with Crohn's disease. Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p &lt;0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.</description><identifier>ISSN: 0034-9887</identifier><identifier>PMID: 16676104</identifier><language>spa</language><publisher>Chile</publisher><subject>Adolescent ; Adult ; Antibodies, Monoclonal - therapeutic use ; Crohn Disease - drug therapy ; Female ; Gastrointestinal Agents - therapeutic use ; Humans ; Infliximab ; Male ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Revista medíca de Chile, 2006-03, Vol.134 (3), p.320-325</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16676104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gellona V, José</creatorcontrib><creatorcontrib>Zarraonandia A, Antón</creatorcontrib><creatorcontrib>Zúñiga D, Alvaro</creatorcontrib><creatorcontrib>Palma C, Renato</creatorcontrib><creatorcontrib>Contreras P, Jaime</creatorcontrib><creatorcontrib>Silva Ch, Jaime</creatorcontrib><creatorcontrib>González D, Róbinson</creatorcontrib><creatorcontrib>Quintana V, Carlos</creatorcontrib><title>Infliximab in the treatment of patients with Crohn's disease: preliminary report</title><title>Revista medíca de Chile</title><addtitle>Rev Med Chil</addtitle><description>Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess the effectiveness of Infliximab in patients with Crohn's disease. Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p &lt;0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Crohn Disease - drug therapy</subject><subject>Female</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0034-9887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNo1kM1KxDAYRbNQnHH0FSQrXRWSNGkbd1L8GRjQha7L1_QLjfQnJik6b2_BcXXP4nDh3jOyZSyXma6qckMuY_xkTJQFry7IhhfFSkxuydt-soP7cSO01E009UhTQEgjTonOlnpIbsVIv13qaR3mfrqLtHMRIeI99QEHN7oJwpEG9HNIV-TcwhDx-pQ78vH0-F6_ZIfX5339cMg8z3XKqk6BMJaBlYKDAq01Y1pIBaoVSnQWhWFtBW1ZKZ3bQurOcGOtYp1pCzD5jtz-9fowfy0YUzO6aHAYYMJ5iU1Rasm5FKt4cxKXdsSu8WEdG47N_wf5LzecWGY</recordid><startdate>200603</startdate><enddate>200603</enddate><creator>Gellona V, José</creator><creator>Zarraonandia A, Antón</creator><creator>Zúñiga D, Alvaro</creator><creator>Palma C, Renato</creator><creator>Contreras P, Jaime</creator><creator>Silva Ch, Jaime</creator><creator>González D, Róbinson</creator><creator>Quintana V, Carlos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200603</creationdate><title>Infliximab in the treatment of patients with Crohn's disease: preliminary report</title><author>Gellona V, José ; Zarraonandia A, Antón ; Zúñiga D, Alvaro ; Palma C, Renato ; Contreras P, Jaime ; Silva Ch, Jaime ; González D, Róbinson ; Quintana V, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-8d5a2cf0af421a5a999009245a5b252dfe2c0b8ab78593f649dc1cff50dcb6ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Crohn Disease - drug therapy</topic><topic>Female</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gellona V, José</creatorcontrib><creatorcontrib>Zarraonandia A, Antón</creatorcontrib><creatorcontrib>Zúñiga D, Alvaro</creatorcontrib><creatorcontrib>Palma C, Renato</creatorcontrib><creatorcontrib>Contreras P, Jaime</creatorcontrib><creatorcontrib>Silva Ch, Jaime</creatorcontrib><creatorcontrib>González D, Róbinson</creatorcontrib><creatorcontrib>Quintana V, Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Revista medíca de Chile</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gellona V, José</au><au>Zarraonandia A, Antón</au><au>Zúñiga D, Alvaro</au><au>Palma C, Renato</au><au>Contreras P, Jaime</au><au>Silva Ch, Jaime</au><au>González D, Róbinson</au><au>Quintana V, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab in the treatment of patients with Crohn's disease: preliminary report</atitle><jtitle>Revista medíca de Chile</jtitle><addtitle>Rev Med Chil</addtitle><date>2006-03</date><risdate>2006</risdate><volume>134</volume><issue>3</issue><spage>320</spage><epage>325</epage><pages>320-325</pages><issn>0034-9887</issn><abstract>Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess the effectiveness of Infliximab in patients with Crohn's disease. Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug. CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p &lt;0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%. A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.</abstract><cop>Chile</cop><pmid>16676104</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0034-9887
ispartof Revista medíca de Chile, 2006-03, Vol.134 (3), p.320-325
issn 0034-9887
language spa
recordid cdi_proquest_miscellaneous_67941142
source SciELO
subjects Adolescent
Adult
Antibodies, Monoclonal - therapeutic use
Crohn Disease - drug therapy
Female
Gastrointestinal Agents - therapeutic use
Humans
Infliximab
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
title Infliximab in the treatment of patients with Crohn's disease: preliminary report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A02%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20in%20the%20treatment%20of%20patients%20with%20Crohn's%20disease:%20preliminary%20report&rft.jtitle=Revista%20med%C3%ADca%20de%20Chile&rft.au=Gellona%20V,%20Jos%C3%A9&rft.date=2006-03&rft.volume=134&rft.issue=3&rft.spage=320&rft.epage=325&rft.pages=320-325&rft.issn=0034-9887&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E67941142%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p139t-8d5a2cf0af421a5a999009245a5b252dfe2c0b8ab78593f649dc1cff50dcb6ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67941142&rft_id=info:pmid/16676104&rfr_iscdi=true